PURPOSE: Cancer testis antigens (CTA) are a class of tumor associated antigens, showing a restricted expression in cancer, a strong immunogenicity and weak expression or absence in normal tissues. CTA are a growing family of proteins involved in signal transduction control. Sp17/AKAP4/PTTG1 have been previously investigated, showing promising results as a target antigens. Our aim was to investigate the expression of Sp17/AKAP4/PTTG1 in lung cancer patients.
METHODS: We analyzed 2 lung cancer cell lines, one normal bronchus cell line, a panel of normal tissues. We studied 17 NSCLC lung cancer patient’s cells by RT-PCR, flow-cytometry, immunocytochemistry, and immunofluorescence. CTA immunogenicity was investigated by measuring circulating specific antibodies in the sera of lung cancer patients. PCR was performed by 35 amplification cycles. RNA integrity in each sample was checked by amplification of β-actin. PCR analysis did not show positive signal bands for any tissue, except for the positive control (testis).
RESULTS: CTA, Sp17, AKAP-4 and PTTG-1 are aberrantly expressed in lung cancer cell lines and primary cells from patients by RT-PCR, immunocytochemistry, and flow cytometry. ELISA analyses show the presence of circulating CTA-specific antibodies in the sera of lung cancer patients, indicating the immunogenicity of Sp17, AKAP-4 and PTTG-1.
CONCLUSIONS: We showed that CTA, Sp17, AKAP-4 and PTTG-1 can be detected in both sera and tissue of patients with NSCLC. These may be used as a component of a lung cancer-screening program. They are potential therapeutic targets as well.
CLINICAL IMPLICATIONS: CTA would be novel targets in generating polyvalent vaccines to reduce the chance of tumor escape. Further work is warranted to develop CTA -tailored immunotherapeutic strategies for non-small cell lung cancer.
DISCLOSURE: The following authors have nothing to disclose: Raed Alalawi, Minji Kim, Leonardo Mirandola, Yuefei Yu, Chompunut Asawa, Lukman Tijani, Cynthia Jumper, Everardo Cobos, Marjorie Jenkins, Maurizio Chiriva-Internati
No Product/Research Disclosure Information